A multicentre randomised controlled trial of intravenous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)

Health Technology Assessment

Volumn 21, Issue 31, 2017, Pages 1-50

  Absoud, Michael ^a   Brex, Peter ^a   Ciccarelli, Olga ^b   Diribe, Onyinye ^a,c   Giovannoni, Gavin ^d   Hellier, Jennifer ^c   Howe, Rosemary ^c   Holland, Rachel ^c   Kelly, Joanna ^c   McCrone, Paul ^c   Murphy, Caroline ^c   Palace, Jackie ^e   Pickles, Andrew ^c   Pike, Michael ^e   Robertson, Neil ^f   Jacob, Anu ^g   Lim, Ming ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^g WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; ANTIINFLAMMATORY AGENT; METHYLPREDNISOLONE;

ACUTE DISEASE; ACUTE KIDNEY FAILURE; ADULT; AGED; ALLERGIC REACTION; AMERICAN SPINAL INJURY ASSOCIATION IMPAIRMENT SCALE; ANAPHYLAXIS; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ASIA MOTOR AND SENSORY SCALE; BACKACHE; CEREBROVASCULAR ACCIDENT; CHILD; CHILL; CLIENT SERVICE RECEIPT INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG COST; DYSPNEA; EARLY INTERVENTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INTERNATIONAL SPINAL CORD INJURY PAIN; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MYELITIS; NAUSEA; OUTCOME ASSESSMENT; PAIN BLADDER AND BOWEL BASIC DATA SETS; PARALLEL DESIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RIGOR; SHOCK; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; ADOLESCENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISABILITY; ECONOMICS; GERMANY; METHODOLOGY; MIDDLE AGED;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYELITIS, TRANSVERSE; QUALITY OF LIFE; RESEARCH DESIGN; SINGLE-BLIND METHOD;

EID: 85021304503     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta21310     Document Type: Article

References (42)

1. Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis. Curr Opin Neurol 2002;15:339–47. https://doi.org/10.1097/00019052-200206000-00019
2. Borchers AT, Gershwin ME. Transverse myelitis. Autoimmun Rev 2012;11:231–48 http://dx.doi.org/10.1016/j.autrev.2011.05.018
3. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499–505. https://doi.org/10.1212/WNL.59.4.499
4. Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatr 2013;84:922–30. http://dx.doi.org/10.1136/jnnp-2012-302310
5. Altrocchi PH. Acute transverse myelopathy. Arch Neurol 1963;9:111–19. https://doi.org/10.1001/archneur.1963.00460080021002
6. Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist 2005;11:2–18. https://doi.org/10.1097/01.nrl.0000149975.39201.0b
7. de Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005;65:1950–3. https://doi.org/10.1212/01.wnl.0000188896.48308.26
8. Absoud M, Lim M, Wassmer E. Inflammatory, Metabolic, Vascular, and Demyelinating Disorders. In Michael Pike, editor. Disorders of the Spinal Cord in Children. London: Mac Keith Press; 2013. pp. 152–85.
9. Young J, Quinn S, Hurrell M, Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009;15:1295–302. https://doi.org/10.1177/1352458509345906
10. Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013;19:76–86. https://doi.org/10.1177/1352458512445944
11. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007;68:1614–17. https://doi.org/10.1212/01.wnl.0000260970.63493.c8
12. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl JMed 2010;363:564–72. http://dx.doi.org/10.1056/NEJMcp1001112
13. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG, Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77:2128–34. https://doi.org/10.1212/WNL.0b013e31823dc535
14. Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–86. https://doi.org/10.1002/1531-8249(199912)46:6<878::AIDANA10> 3.0.CO;2-Q
15. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009;158(Suppl. 1):34–42 http://dx.doi.org/10.1111/j.1365-2249.2009.04025.x
16. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007;6:887–902. https://doi.org/10.1016/S1474-4422(07)70242-9
17. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501–4. https://doi.org/10.1177/1352458513495938
18. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51:S2–8. https://doi.org/10.1212/WNL.51.6_Suppl_5.S2
19. Awad A, Stuve O. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol 2011;9:417–28. https://doi.org/10.2174/157015911796557948
20. Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007;45:206–21. https://doi.org/10.1038/sj.sc.3102008
21. Savic G, Bergstrom EM, Frankel HL, Jamous MA, Jones PW. Inter-rater reliability of motor and sensory examinations performed according to American Spinal Injury Association standards. Spinal Cord 2007;45:444–51. https://doi.org/10.1038/sj.sc.3102044
22. Sepülveda M, Blanco Y, Rovira A, Rio J, Mendibe M, Llufriu S, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler 2013;19:742–8. https://doi.org/10.1177/1352458512461968
23. Scott D, Ferguson GD, Jelsma J. The use of the EQ-5D-Y health related quality of life outcome measure in children in the Western Cape, South Africa: psychometric properties, feasibility and usefulness –a longitudinal, analytical study. Health Qual Life Outcomes 2017;15:12. https://doi.org/10.1186/s12955-017-0590-3
24. Whitehurst DG, Mittmann N, Noonan VK, Dvorak MF, Bryan S. Health state descriptions, valuations and individuals’ capacity to walk: a comparative evaluation of preference-based instruments in the context of spinal cord injury. Qual Life Res 2016;25:2481–96. https://doi.org/10.1007/s11136-016-1297-3
25. Biering-Sørensen F, Charlifue S, DeVivo M, Noonan V, Post M, Stripling T, Wing P. International Spinal Cord Injury Data Sets. Spinal Cord 2006;44:530–4 http://dx.doi.org/10.1038/sj.sc.3101930
26. Mahdi-Rogers M, McCrone P, Hughes RA. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014;21:34–9. https://doi.org/10.1111/ene.12245
27. Juul T, Bazzocchi G, Coggrave M, Johannesen IL, Thiyagarajan CC, Poletti E, et al. Reliability of the International Spinal Cord Injury Bowel Function Basic and Extended Data Sets. Spinal Cord 2011;49:886–91. https://doi.org/10.1038/sc.2011.23
28. Goetz LL, Cardenas DD, Kennelly M, Bonne Lee BS, Linsenmeyer T, Moser C, et al. International Spinal Cord Injury Urinary Tract Infection Basic Data Set. Spinal Cord 2013;51:700–4. https://doi.org/10.1038/sc.2013.72
29. Buck D. The PedsQL as a measure of parent-rated quality of life in healthy UK toddlers: psychometric properties and cross-cultural comparisons. J Child Health Care 2012;16:331–8. https://doi.org/10.1177/1367493512448127
30. Oladeji O, Johnston TE, Smith BT, Mulcahey MJ, Betz RR, Lauer RT. Quality of life in children with spinal cord injury. Pediatr Phys Ther 2007;19:296–300. https://doi.org/10.1097/PEP.0b013e31815a12ef
31. Mahnig S, Landmann G, Stockinger L, Opsommer E. Pain assessment according to the International Spinal Cord Injury Pain classification in patients with spinal cord injury referred to a multidisciplinary pain center. Spinal Cord 2016;54:809–15. https://doi.org/10.1038/sc.2015.219
32. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–9. https://doi.org/10.1212/01.wnl.0000216139.44259.74
33. Absoud M, Gadian J, Hellier J, Brex PA, Ciccarelli O, Giovannoni G, et al. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ Open 2015;5:e008312.
34. Medicines and Healthcare products Regulatory Agency. Good Clinical Practice for Clinical Trials. 2014. URL: www.gov.uk/guidance/good-clinical-practice-for-clinical-trials (accessed 30 March 2017).
35. US Food and Drug Administration. CFR –Code of Federal Regulations Title 21. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11&showFR=1 (accessed 30 March 2017).
36. European Commission. Medicinal Products for Human Use. URL: https://ec.europa.eu/health/human-use/clinical-trials_en (accessed 30 March 2017).
37. Great Britain. Statutory Instruments: 2004 No. 1031 –Medicines. The Medicines for Human Use (Clinical Trials) Regulations 2004 –Regulation 46(2). 31 March 2004. URL: www.legislation.gov.uk/uksi/2004/1031/pdfs/uksi_20041031_en.pdf (accessed 30 March 2017).
38. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
39. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40 http://dx.doi.org/10.1136/bmj.d40
40. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, et al. Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003;10:687–94. https://doi.org/10.1046/j.1351-5101.2003. 00701.x
41. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 2014;9:170 http://dx.doi.org/10.1186/s13023-014-0170-0
42. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009;96:20–6 http://dx.doi.org/10.1016/j.ymgme.2008.10.003